You are here


Scientist working on radiooncology imaging

Imaging modalities are becoming one of the most effective means of detecting cancer and a crucial component of patient care. We have a strong track record of funding cancer imaging research by scientists, clinicians and healthcare workers across the UK.

Our imaging research grant funding

Support for imaging research is available across a broad range of our funding opportunities including:

Our Translation Managers and Business Development Managers are actively involved in evaluating applications. We have exclusive commercialisation rights to newly generated IP arising from these imaging research awards.

National Cancer Imaging Translational Accelerator (NCITA) infrastructure

We also support a network of translational cancer imaging infrastructure, namely the National Cancer Imaging Translational Accelerator (NCITA) through our Accelerator Award.

In 2018, following a strategic review of our investment into translational research infrastructure, we granted Accelerator Award funding to establish NCITA. This 5-year initiative brings together 9 medical imaging centres of excellence across the UK. This network will develop the necessary infrastructure to accelerate the standardisation and clinical translation of cancer imaging biomarkers to improve diagnosis and healthcare outcomes for people affected by cancer.

Our NCITA partners are:

  • The University of Oxford
  • The Institute of Cancer Research, London
  • King’s College London
  • University College London
  • The University of Cambridge
  • The University of Manchester
  • Imperial College London
  • The University of Glasgow
  • Newcastle University

Through this network we are supporting an initial portfolio of exemplar projects. Our Translation Managers and Business Development Managers work closely with NCITA leaders to establish the best commercial model to ensure new discoveries arising from the exemplar projects and other studies supported by Cancer Research UK become available to people with cancer.

Visit our Imaging agent for prostate and glioma detection webpage for more information on an opportunity to co-develop or license the imaging tracer 18F-FPIA for prostate or glioma detection investigated in NCITA Exemplar 1.

A key goal of the NCITA network is to establish the necessary infrastructure to facilitate the translation of novel clinical research studies in collaboration with external partners, from both academia and industry. For more information, see the NCITA Comment article published in the British Journal of Cancer.

The NCITA team are keen to discuss new external studies with investigators and explore opportunities to access the network’s expertise and infrastructure for multicentre clinical imaging studies.

Visit the NCITA site to find out more about NCITA’s study adoption process